404 related articles for article (PubMed ID: 35311620)
1. Fat mass and obesity associated (FTO)-mediated N6-methyladenosine modification of Krüppel-like factor 3 (KLF3) promotes osteosarcoma progression.
Shan HJ; Gu WX; Duan G; Chen HL
Bioengineered; 2022 Apr; 13(4):8038-8050. PubMed ID: 35311620
[TBL] [Abstract][Full Text] [Related]
2. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.
Niu Y; Lin Z; Wan A; Chen H; Liang H; Sun L; Wang Y; Li X; Xiong XF; Wei B; Wu X; Wan G
Mol Cancer; 2019 Mar; 18(1):46. PubMed ID: 30922314
[TBL] [Abstract][Full Text] [Related]
3. The tumor-suppressive effects of alpha-ketoglutarate-dependent dioxygenase FTO via N6-methyladenosine RNA methylation on bladder cancer patients.
Yi W; Yu Y; Li Y; Yang J; Gao S; Xu L
Bioengineered; 2021 Dec; 12(1):5323-5333. PubMed ID: 34499008
[TBL] [Abstract][Full Text] [Related]
4. FTO demethylates m6A modifications in HOXB13 mRNA and promotes endometrial cancer metastasis by activating the WNT signalling pathway.
Zhang L; Wan Y; Zhang Z; Jiang Y; Lang J; Cheng W; Zhu L
RNA Biol; 2021 Sep; 18(9):1265-1278. PubMed ID: 33103587
[TBL] [Abstract][Full Text] [Related]
5. m
Liu J; Ren D; Du Z; Wang H; Zhang H; Jin Y
Biochem Biophys Res Commun; 2018 Aug; 502(4):456-464. PubMed ID: 29842885
[TBL] [Abstract][Full Text] [Related]
6. FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner.
Huang J; Sun W; Wang Z; Lv C; Zhang T; Zhang D; Dong W; Shao L; He L; Ji X; Zhang P; Zhang H
J Exp Clin Cancer Res; 2022 Jan; 41(1):42. PubMed ID: 35090515
[TBL] [Abstract][Full Text] [Related]
7. Methylation recognition protein YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) regulates the proliferation, migration and invasion of osteosarcoma by regulating m6A level of CCR4-NOT transcription complex subunit 7 (CNOT7).
Wei K; Gao Y; Wang B; Qu YX
Bioengineered; 2022 Mar; 13(3):5236-5250. PubMed ID: 35156522
[TBL] [Abstract][Full Text] [Related]
8. FTO facilitates cancer metastasis by modifying the m
Gao L; Wang A; Chen Y; Cai X; Li Y; Zhao J; Zhang Y; Zhang W; Zhu J; Zeng Y; Liu Z; Huang JA
Cell Commun Signal; 2023 Nov; 21(1):311. PubMed ID: 37919739
[TBL] [Abstract][Full Text] [Related]
9. N6-Methyladenosine Demethylase FTO (Fat Mass and Obesity-Associated Protein) as a Novel Mediator of Statin Effects in Human Endothelial Cells.
Mo W; Chen Z; Zhang X; Dai G; Ma D; Pan J; Zhang X; Wu G; Fan W
Arterioscler Thromb Vasc Biol; 2022 May; 42(5):644-658. PubMed ID: 35296150
[TBL] [Abstract][Full Text] [Related]
10. RNA m6A demethylase FTO-mediated epigenetic up-regulation of LINC00022 promotes tumorigenesis in esophageal squamous cell carcinoma.
Cui Y; Zhang C; Ma S; Li Z; Wang W; Li Y; Ma Y; Fang J; Wang Y; Cao W; Guan F
J Exp Clin Cancer Res; 2021 Sep; 40(1):294. PubMed ID: 34544449
[TBL] [Abstract][Full Text] [Related]
11. RNA N6-methyladenosine demethylase FTO promotes osteoporosis through demethylating Runx2 mRNA and inhibiting osteogenic differentiation.
Wang J; Fu Q; Yang J; Liu JL; Hou SM; Huang X; Cao JS; Liu TL; Wang KZ
Aging (Albany NY); 2021 Sep; 13(17):21134-21141. PubMed ID: 34496349
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of USP18/FTO/PYCR1 signaling network promotes bladder cancer development and progression.
Song W; Yang K; Luo J; Gao Z; Gao Y
Aging (Albany NY); 2021 Jan; 13(3):3909-3925. PubMed ID: 33461172
[TBL] [Abstract][Full Text] [Related]
13. FTO promotes the progression of retinoblastoma through YTHDF2-dependent N6-methyladenosine modification in E2F3.
Xie W; Shao Y; Bo Q; Li Z; Yu Q; Wang L; Wu G
Mol Carcinog; 2024 May; 63(5):926-937. PubMed ID: 38380957
[TBL] [Abstract][Full Text] [Related]
14. M
Lv D; Ding S; Zhong L; Tu J; Li H; Yao H; Zou Y; Zeng Z; Liao Y; Wan X; Wen L; Xie X
Oncogene; 2022 Mar; 41(12):1727-1741. PubMed ID: 35121825
[TBL] [Abstract][Full Text] [Related]
15. LncRNA FTO-IT1 promotes glycolysis and progression of hepatocellular carcinoma through modulating FTO-mediated N6-methyladenosine modification on GLUT1 and PKM2.
Wang F; Hu Y; Wang H; Hu P; Xiong H; Zeng Z; Han S; Wang D; Wang J; Zhao Y; Huang Y; Zhuo W; Lv G; Zhao G
J Exp Clin Cancer Res; 2023 Oct; 42(1):267. PubMed ID: 37840133
[TBL] [Abstract][Full Text] [Related]
16. m
Wang X; Wu R; Liu Y; Zhao Y; Bi Z; Yao Y; Liu Q; Shi H; Wang F; Wang Y
Autophagy; 2020 Jul; 16(7):1221-1235. PubMed ID: 31451060
[TBL] [Abstract][Full Text] [Related]
17. ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner.
Yang Z; Cai Z; Yang C; Luo Z; Bao X
EBioMedicine; 2022 Jun; 80():104019. PubMed ID: 35490460
[TBL] [Abstract][Full Text] [Related]
18. The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1.
Miao W; Chen J; Jia L; Ma J; Song D
Biochem Biophys Res Commun; 2019 Aug; 516(3):719-725. PubMed ID: 31253399
[TBL] [Abstract][Full Text] [Related]
19. FTO promotes proliferation and migration of bladder cancer via enhancing stability of STAT3 mRNA in an m6A-dependent manner.
Sun Z; Sun X; Qin G; Li Y; Zhou G; Jiang X
Epigenetics; 2023 Dec; 18(1):2242688. PubMed ID: 37538000
[TBL] [Abstract][Full Text] [Related]
20. FTO Prevents Thyroid Cancer Progression by SLC7A11 m6A Methylation in a Ferroptosis-Dependent Manner.
Ji FH; Fu XH; Li GQ; He Q; Qiu XG
Front Endocrinol (Lausanne); 2022; 13():857765. PubMed ID: 35721711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
